This page lists the medical oncology hospitals in our directory offering Bone Marrow Transplant in Chennai, India, including Apollo Hospitals, Greams Road, Gleneagles Global Hospital, Dr. Rela Institute and Medical Centre, SIMS Hospital and others. Each listing links through to the hospital's full profile page.
Ask us about bone marrow transplant in Chennai, India
Share a few details and our care coordination team will get back to you with next steps.
Compare 8 accredited hospitals for Medical Oncology in Chennai, India
Featured🇮🇳 Apollo Hospitals, Greams Road
Ranks #1 in this list by listed rating (4.7/5 from 125 reviews).
🇮🇳 Gleneagles Global Hospital
Ranks #2 in this list by listed rating (4.7/5 from 112 reviews).
🇮🇳 Dr. Rela Institute and Medical Centre
Ranks #3 in this list by listed rating (4.7/5 from 108 reviews).
🇮🇳 SIMS Hospital
Ranks #4 in this list by listed rating (4.6/5 from 20 reviews).
🇮🇳 Sankara Nethralaya
Ranks #5 in this list by listed rating (4.4/5 from 220 reviews).
🇮🇳 Apollo First Med Hospitals, Kilpauk
Ranks #6 in this list by listed rating (4.4/5 from 76 reviews).
🇮🇳 MIOT International
Ranks #7 in this list by listed rating (4.4/5 from 200 reviews).
🇮🇳 MGM Healthcare
Ranks #8 in this list by listed rating (3.7/5 from 34 reviews).
How we selected these hospitals
A hospital appears on this page when Medical Oncology is among its listed specialties and it is located in Chennai, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How to Select the Best Hospital for Bone Marrow Transplant in Chennai, India?
Choosing the right hospital for bone marrow transplant is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:
International Accreditation
Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.
Specialization
Check that the hospital's listed specialties actually include medical oncology rather than only general care.
Capacity and Track Record
Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.
Transparent Costs
Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.
Understanding Bone Marrow Transplant
Bone Marrow Transplant (BMT) — encompassing autologous, allogeneic, and haploidentical stem cell transplantation — is a potentially curative treatment for hematological malignancies, bone marrow failure syndromes, and select immune deficiencies, with disease-free survival rates ranging from 50% to 80% depending on diagnosis, donor match, and conditioning regimen. Leading transplant centres in India and the UAE offer internationally accredited BMT programs staffed by haematologist-oncologists trained at globally recognised institutions, using reduced-intensity conditioning (RIC), myeloablative conditioning (MAC), and advanced graft-versus-host disease (GvHD) prophylaxis protocols that are fully aligned with EBMT and ASBMT guidelines. GAF Healthcare coordinates end-to-end medical travel for international patients seeking BMT in India or the UAE, providing access to JCI- and NABH-accredited centres in India (typically at 40–60% lower cost) and JCI- and DHA-accredited premium facilities in Dubai and Abu Dhabi, combined with dedicated case management from first consultation through long-term follow-up. Hospital Stay: 30–60 days (inpatient sterile isolation unit, varies by transplant type and engraftment timeline) • Total Stay in Country (Fit-to-Fly): 10–16 weeks (patients must achieve stable engraftment, discontinue IV immunosuppression, and clear infectious screening before long-haul flight is medically safe) • Success Rate: 50–80% disease-free survival at 5 years (highly dependent on diagnosis, disease stage, donor HLA match, and conditioning regimen)
Clinical Overview
Bone marrow transplantation — more precisely termed haematopoietic stem cell transplantation (HSCT) — replaces a patient's diseased or ablated haematopoietic system with healthy stem cells capable of reconstituting normal blood cell lineages. The procedure is indicated when the bone marrow fails to produce adequate functional blood cells, either due to intrinsic disease (aplastic anaemia, myelodysplastic syndrome), malignant infiltration (acute myeloid leukaemia, acute lymphoblastic leukaemia, multiple myeloma, lymphomas), or as a consolidation strategy following induction chemotherapy in high-risk disease. In allogeneic transplantation, the donor's immune system also confers a graft-versus-leukaemia (GvL) effect, actively suppressing residual malignant clones — a therapeutic mechanism distinct from chemotherapy alone. The physiological impact of BMT is profound and multi-systemic. Conditioning regimens — either myeloablative (high-dose busulfan/cyclophosphamide or total body irradiation-based) or reduced-intensity (fludarabine-based combinations) — render the patient profoundly immunocompromised and pancytopenic for 2–4 weeks until donor engraftment occurs. During this period, patients are at extreme risk of opportunistic bacterial, fungal (Aspergillus, Candida), and viral (CMV, EBV, adenovirus) infections and require strict isolation in HEPA-filtered positive-pressure rooms, prophylactic antifungals (posaconazole or voriconazole), antivirals (aciclovir, valganciclovir), and prophylactic antibiotics. Engraftment — defined as an absolute neutrophil count exceeding 0.5 × 10⁹/L on three consecutive days — typically occurs by day +14 to +21 post-infusion. The current standard of care at high-volume centres integrates pre-transplant minimal residual disease (MRD) assessment by multiparameter flow cytometry or next-generation sequencing to confirm remission depth before conditioning, HLA-typing at allele-level resolution (10/10 or 12/12 match for unrelated donors), and post-transplant cyclophosphamide (PTCy) protocols — now the dominant platform for haploidentical transplantation — which have dramatically expanded the donor pool to virtually any first-degree relative. Centres in India and the UAE managing international patients additionally use EBMT risk score stratification, CMV serostatus-guided prophylaxis, and standardised GvHD grading (Mount Sinai Acute GVHD International Consortium criteria) to ensure globally benchmarked outcomes.
Who is a Candidate?
ELIGIBLE DIAGNOSES & INDICATIONS: • Acute Myeloid Leukaemia (AML): intermediate- or adverse-risk cytogenetics (e.g., monosomy 7, complex karyotype, FLT3-ITD without NPM1), or relapsed/refractory disease in CR1 or CR2 • Acute Lymphoblastic Leukaemia (ALL): Philadelphia chromosome-positive ALL, MRD-positive after induction, or high-risk features (e.g., hypodiploidy, KMT2A rearrangement) • Myelodysplastic Syndrome (MDS): IPSS-R score intermediate or above, or therapy-related MDS • Chronic Myeloid Leukaemia (CML): TKI-refractory accelerated or blast phase • Multiple Myeloma: autologous HSCT post-induction (bortezomib/lenalidomide/dexamethasone or daratumumab-based regimens) as standard consolidation for transplant-eligible patients under 70 • Non-Hodgkin Lymphoma: relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma sensitive to salvage chemotherapy (autologous HSCT); or allogeneic for chemorefractory disease • Hodgkin Lymphoma: relapsed/refractory disease after second-line therapy, PET-negative before transplant • Aplastic Anaemia: severe or very severe (SAA/vSAA) failing immunosuppression, or upfront allogeneic HSCT in patients under 40 with matched sibling donors • Haemoglobinopathies: sickle cell disease (Glucksberg Class I–II) and transfusion-dependent thalassaemia major in paediatric and young adult patients • Primary Immunodeficiencies: SCID, Wiskott-Aldrich syndrome, chronic granulomatous disease REQUIRED PRE-TRANSPLANT DIAGNOSTICS: • Bone marrow biopsy with cytogenetics (conventional karyotype + FISH panel), flow cytometry immunophenotyping, and MRD quantification (NGS-MRD preferred) • HLA typing (patient and all potential donors) at high-resolution allele level: HLA-A, -B, -C, -DRB1, -DQB1 • PET-CT scan (for lymphoma patients to confirm chemosensitivity before conditioning) • Cardiac evaluation: 2D echocardiography (LVEF must be ≥ 45–50%), ECG, and NT-proBNP if cardiotoxic prior therapy used • Pulmonary Function Tests (PFTs): DLCO must be ≥ 50% predicted; CT chest to exclude occult fungal or bacterial infection • Renal function (GFR ≥ 50 mL/min preferred for full myeloablative conditioning) • Liver function, hepatitis B/C serology, HIV, CMV, EBV, HSV, VZV, Toxoplasma IgG serostatus • Dental evaluation and caries clearance before conditioning • Fertility counselling and cryopreservation discussion (sperm/oocyte banking) prior to gonadotoxic conditioning • Psychosocial assessment and nutritional status (BMI, albumin, pre-transplant functional status using Karnofsky/Lansky score) CONTRAINDICATIONS: • LVEF < 40% or uncontrolled heart failure • DLCO < 40% predicted or active pulmonary infection • Uncontrolled active infection (bacterial, fungal, or viral) at time of planned conditioning • Severe hepatic dysfunction (Child-Pugh C cirrhosis or bilirubin > 2× ULN unless disease-related) • Active, uncontrolled malignancy not responsive to salvage therapy (chemorefractory disease is a relative contraindication for allogeneic HSCT; must demonstrate at least partial response) • Karnofsky Performance Status < 60% (relative contraindication; RIC regimens may allow PS 50–60%) • Significant, uncontrolled psychiatric illness that would preclude adherence to strict isolation and complex medication regimens • Age > 70 years for myeloablative conditioning (RIC regimens extend eligibility to age 75 in select patients with excellent organ function)
Treatment Options & Approaches
AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION (Auto-HSCT): The patient's own peripheral blood stem cells (PBSCs) are mobilised using G-CSF (filgrastim or plerixafor-augmented mobilisation for poor mobilisers), collected by leukapheresis, cryopreserved in liquid nitrogen, and re-infused after high-dose conditioning chemotherapy. Standard conditioning regimens include BEAM (carmustine, etoposide, cytarabine, melphalan) for lymphomas and high-dose melphalan (200 mg/m²) for multiple myeloma. Tandem autologous transplantation is considered for high-risk myeloma (ISS Stage III, high-risk cytogenetics such as del(17p), t(4;14), gain(1q)). Because the patient's own cells are reinfused, there is no GvH disease risk, but also no GvL effect; relapse risk depends entirely on disease biology and consolidation/maintenance therapy (e.g., lenalidomide maintenance post-auto in myeloma, per IFM 2005-02 and CALGB 100104 trial data). ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION (Allo-HSCT) — MATCHED SIBLING DONOR (MSD): Considered the gold standard for allogeneic transplantation. A 10/10 HLA-matched sibling provides the lowest GvHD risk and best GvL effect. Conditioning is either myeloablative (BuCy: busulfan IV 3.2 mg/kg/day × 4 days + cyclophosphamide; or TBI 12 Gy fractionated + cyclophosphamide) or reduced-intensity (Flu/Bu2: fludarabine + 2-day busulfan, appropriate for patients over 50 or with organ comorbidities). GvHD prophylaxis: calcineurin inhibitor (tacrolimus or cyclosporine) + methotrexate (short-course) or mycophenolate mofetil (MMF). ALLOGENEIC HSCT — MATCHED UNRELATED DONOR (MUD) VIA BONE MARROW REGISTRY: When no matched sibling is available, high-resolution HLA-matched unrelated donors are sourced from international registries (NMDP/Be The Match, DKMS, DATRI in India). A 10/10 MUD match carries GvHD risk intermediate between MSD and haploidentical. Post-transplant cyclophosphamide (PTCy: 50 mg/kg on days +3 and +4) is increasingly used as GvHD prophylaxis in the MUD setting, replacing or augmenting conventional CNI-based approaches. HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (Haplo-PTCy): A transformative advance pioneered at Johns Hopkins and validated globally, Haplo-PTCy uses a 50% HLA-matched first-degree relative (parent, child, or sibling) as the donor. Because virtually every patient has at least one haploidentical relative, the donor search phase is eliminated, reducing time-to-transplant significantly — critical in aggressive leukaemias. PTCy selectively eliminates alloreactive T-cells proliferating early post-infusion while sparing regulatory and memory T-cells, resulting in GvHD rates comparable to MUD transplants. Major transplant centres in India and the UAE now report Haplo-PTCy outcomes — including non-relapse mortality, 2-year overall survival, and GvHD-free relapse-free survival (GRFS) — equivalent to matched donor transplants for AML in CR1. UMBILICAL CORD BLOOD TRANSPLANTATION (UCBT): Used when no matched adult donor is available and time is critical, or in paediatric patients. Double cord blood units are used in adults to provide sufficient cell dose. Engraftment is slower (day +21 to +35) and the risk of graft failure is higher, but the lower HLA-match requirement and the immunological naivety of cord-derived T-cells reduce chronic GvHD rates. Select centres in India (particularly in major metropolitan cities) and the UAE maintain cord blood bank partnerships. BONE MARROW HARVEST (Surgical) vs. PERIPHERAL BLOOD STEM CELL (PBSC) COLLECTION: Stem cells for allogeneic transplant are collected either by surgical bone marrow harvest under general anaesthesia (600–1000 mL aspirated from posterior iliac crests) or by G-CSF-mobilised leukapheresis of peripheral blood. PBSC grafts engraft faster and are used most commonly; marrow grafts may be preferred in aplastic anaemia and haemopoietic syndromes where lower T-cell content reduces chronic GvHD risk, per IBMTR data. CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY (CAR-T) AS AN ALTERNATIVE OR BRIDGE: For relapsed/refractory B-cell ALL and large B-cell lymphoma, CAR-T therapy (tisagenlecleucel, axicabtagene ciloleucel, lisocabtagene maraleucel) represents an emerging alternative or bridge strategy before allo-HSCT consolidation. Select advanced oncology centres in India and the UAE now offer commercially approved CAR-T programmes or clinical trial access. GAF Healthcare can facilitate evaluation for CAR-T eligibility in conjunction with or as a preceding step to BMT planning. GRAFT-VERSUS-HOST DISEASE (GvHD) PROPHYLAXIS & TREATMENT TECHNOLOGIES: • Acute GvHD prophylaxis: PTCy-based platforms, calcineurin inhibitors (tacrolimus with target trough 5–15 ng/mL), MMF, anti-thymocyte globulin (ATG: rabbit ATG or equine ATG) • Chronic GvHD management: ruxolitinib (JAK1/2 inhibitor, FDA-approved second-line), ibrutinib (BTK inhibitor), belumosudil (ROCK2 inhibitor), extracorporeal photopheresis (ECP) • CD34+ graft manipulation / T-cell depletion using CliniMACS Prodigy platform for high-risk GvHD scenarios (available at select centres) • Bone Marrow Transplantation Units at top Indian and UAE centres are equipped with ISO Class 5 HEPA-filtered positive-pressure isolation rooms, real-time chimerism monitoring by STR-PCR, and MRD surveillance by flow cytometry and ddPCR at standardised post-transplant intervals (day +30, +100, +180, +365)
Recovery
PHASE 1 — REMOTE PRE-EVALUATION (Weeks 1–4, from home country): Patient submits complete medical records to GAF Healthcare's clinical team, including bone marrow biopsy reports, cytogenetics, flow cytometry, PET-CT scans, echocardiogram, PFTs, and prior treatment history. GAF Healthcare's partnered transplant physician reviews records and provides a detailed second opinion, transplant feasibility assessment, proposed conditioning regimen, and donor strategy recommendation within 5–7 business days. Visa and travel logistics planning commences in parallel. PHASE 2 — ARRIVAL & PRE-TRANSPLANT WORKUP (Days −30 to −10 before conditioning): Patient arrives in India or the UAE and is admitted or seen in outpatient transplant clinic. Comprehensive repeat baseline investigations are performed: repeat bone marrow biopsy and MRD quantification to confirm remission status, updated PFTs, ECHO, ECG, renal and liver function panel, infectious disease serology (CMV, EBV, HSV, hepatitis B/C, HIV, Toxoplasma), and dental clearance. High-resolution HLA typing is confirmed for patient and donor. A central venous catheter (Hickman line or PICC) is placed under ultrasound guidance for conditioning drug delivery, stem cell infusion, and intensive monitoring. Donor undergoes G-CSF mobilisation (if PBSC collection planned) starting 5 days before scheduled infusion, or is admitted for surgical bone marrow harvest. PHASE 3 — CONDITIONING REGIMEN (Days −7 to −1): High-dose or reduced-intensity conditioning chemotherapy (and/or total body irradiation if TBI-based regimen) is administered in the sterile transplant unit. The patient is monitored continuously for mucositis (managed with IV morphine PCA, sucralfate, and cryotherapy), nausea (ondansetron, dexamethasone, aprepitant), haemorrhagic cystitis (MESNA uroprotection, aggressive IV hydration with busulfan/cyclophosphamide regimens), and infectious prophylaxis is initiated: fluconazole or posaconazole, aciclovir, co-trimoxazole (PCP prophylaxis deferred until engraftment). PHASE 4 — STEM CELL INFUSION (Day 0): Cryopreserved autologous cells are thawed and infused at bedside (auto-HSCT), or freshly collected donor PBSCs or marrow are infused via the central line (allo-HSCT). The infusion is administered over 1–4 hours under continuous cardiac and vital sign monitoring. Patients may experience DMSO-related flushing, nausea, or bradycardia during cryopreserved cell infusion, managed with antihistamines, antiemetics, and IV fluids. PHASE 5 — ENGRAFTMENT PHASE & STERILE ISOLATION (Days +1 to +30): The most critical and medically intensive phase. Patient remains in HEPA-filtered positive-pressure isolation room. Prophylactic antibiotics (fluoroquinolones), antifungals, and antivirals are continued. Transfusion support with irradiated, leukodepleted packed red blood cells (haemoglobin threshold 80 g/L) and platelets (threshold 10 × 10⁹/L, or 20 × 10⁹/L if febrile) is provided. Febrile neutropenia episodes are managed with broad-spectrum IV antibiotics (piperacillin-tazobactam or meropenem for resistant organisms) and antifungal escalation (caspofungin or liposomal amphotericin B if fluconazole-resistant suspected). Engraftment is confirmed when ANC > 0.5 × 10⁹/L on three consecutive days — typically by day +14 to +21 for PBSC grafts and day +18 to +28 for marrow grafts. Weekly chimerism testing (STR-PCR) from day +30 confirms donor engraftment percentage. PHASE 6 — EARLY POST-ENGRAFTMENT & GvHD MONITORING (Days +30 to +100): Patient transitions to outpatient transplant clinic (within the country, near the transplant centre) for twice-weekly to weekly review. GvHD prophylaxis medications (tacrolimus/cyclosporine + MMF or PTCy-based regimen) are continued and slowly tapered per protocol. Acute GvHD affecting skin (maculopapular rash), gut (diarrhoea > 500 mL/day), or liver (rising bilirubin) is staged by MAGIC criteria and treated with systemic corticosteroids (methylprednisolone 1–2 mg/kg/day) with rapid escalation to ruxolitinib or ECP for steroid-refractory cases. CMV and EBV reactivation are monitored by weekly quantitative PCR; pre-emptive therapy with valganciclovir or ganciclovir is initiated at defined viral load thresholds. MRD assessment is repeated at day +100. Patients must remain in-country and within accessible distance of the transplant centre throughout this phase. PHASE 7 — FIT-TO-FLY ASSESSMENT (Weeks 10–16 post-infusion): Before international travel is approved, the transplant physician must confirm: (1) stable, full donor engraftment on chimerism testing; (2) no active acute GvHD above Grade I; (3) ANC consistently > 1.0 × 10⁹/L without G-CSF support; (4) transition to oral immunosuppression only, with stable tacrolimus or cyclosporine levels; (5) no active viral reactivation; (6) no recent transfusion dependence; (7) patient and accompanying caregiver are educated on emergency protocols and have confirmed follow-up with a haematologist in the home country. GAF Healthcare coordinates the medical summary, discharge letter, full medication list, and emergency contact details for the receiving haematologist. PHASE 8 — LONG-TERM REMOTE FOLLOW-UP (Months 6–24+): Follow-up visits (which may include return trips to the transplant centre at months 6 and 12 for MRD assessment, chimerism testing, and chronic GvHD evaluation) are coordinated by GAF Healthcare's case management team. Immunisation schedule (live vaccines contraindicated until 24 months post-transplant and off immunosuppression) and vaccination re-priming (diphtheria, tetanus, pertussis, inactivated polio, hepatitis B, pneumococcal, influenza) is planned per EBMT/IDSA guidelines for post-transplant immune reconstitution.
Risks to be aware of
Bone Marrow Transplant carries significant procedure-related morbidity and mortality that must be discussed candidly with every patient. Non-relapse mortality (NRM) — death from transplant-related complications rather than disease relapse — ranges from 5–10% at 1 year for autologous HSCT to 10–25% for allogeneic HSCT depending on donor match, conditioning intensity, and patient comorbidities, as assessed by the HCT-Comorbidity Index (HCT-CI) and EBMT Risk Score. Graft-versus-Host Disease (GvHD) is the most distinctive and clinically significant complication of allogeneic transplantation. Acute GvHD (occurring before day +100) affects the skin, liver, and gastrointestinal tract, with severe Grade III–IV acute GvHD carrying a mortality exceeding 50% despite treatment. Chronic GvHD (after day +100) can affect virtually any organ system — skin (sclerosis), mouth, eyes, lungs (bronchiolitis obliterans syndrome — the most feared pulmonary complication), liver, musculoskeletal system, and genitourinary tract — and significantly impairs quality of life and functional capacity in 30–50% of long-term survivors. Primary graft failure (failure to engraft) occurs in 1–5% of allogeneic transplants and up to 1–2% of autologous transplants, requiring salvage second infusion or alternative donor strategy. Infectious complications during the pre-engraftment and early post-engraftment phases are life-threatening: invasive fungal infections (particularly invasive aspergillosis), CMV pneumonitis, and adenovirus haemorrhagic cystitis are the most feared pathogens. Hepatic sinusoidal obstruction syndrome (SOS/VOD) — a severe hepatic complication of high-dose busulfan or TBI-based conditioning — occurs in 5–15% of patients and is treated with defibrotide in severe cases. Long-term complications include secondary malignancies (therapy-related MDS or AML in autologous transplant recipients; post-transplant lymphoproliferative disorder in allogeneic recipients), endocrine dysfunction (hypothyroidism, gonadal failure, growth hormone deficiency in paediatric patients), avascular necrosis of bone (particularly femoral head, related to corticosteroid use for GvHD), cataracts (especially after TBI conditioning), and cognitive effects ('chemo brain'). Patients receiving TBI-based conditioning should be counselled on the risk of secondary solid tumours over the ensuing decades. All risks are mitigated by careful patient selection (HCT-CI scoring, organ function assessment), centre volume and experience (high-volume centres performing > 100 transplants per year demonstrate lower NRM in registry analyses), and protocol-driven supportive care. GAF Healthcare exclusively partners with centres that meet minimum annual transplant volume thresholds and report outcomes to international registries (EBMT or CIBMTR).
Why GAF Healthcare
GAF Healthcare provides comprehensive, end-to-end non-medical coordination that removes administrative and logistical barriers for international patients and their families throughout the BMT journey — which, given the required in-country stay of 10–16 weeks, is substantially more complex than short-stay medical travel. VISA ASSISTANCE — INDIA: GAF Healthcare's visa team assists patients in applying for the Indian e-Medical Visa (eM-Visa), which allows a stay of up to 60 days per visit with the ability to apply for extensions through the Foreigners Regional Registration Office (FRRO) — essential given BMT's prolonged in-country requirement. A Medical Attendant e-Visa is simultaneously arranged for one accompanying family member or caregiver, covering their stay throughout the transplant and recovery period. GAF provides the official hospital invitation letter, treatment plan, and cost estimate required by Indian immigration authorities for visa approval. VISA ASSISTANCE — UAE (DUBAI / ABU DHABI): Citizens of most GCC, EU, US, UK, Commonwealth, and ASEAN nations receive visa-on-arrival or visa-free entry to the UAE for up to 30–90 days. For the extended stay required for BMT, GAF Healthcare coordinates a Medical Treatment Visa or long-stay extension through the General Directorate of Residency and Foreigners Affairs (GDRFA Dubai) or Abu Dhabi Immigration, in collaboration with the treating hospital. The attending hospital's patient services team, coordinated by GAF, provides the necessary documentation. AIRPORT TRANSFERS & GROUND LOGISTICS: GAF Healthcare arranges private, climate-controlled vehicle transfers between the international airport and the hospital or accommodation at every stage — arrival, inter-facility transfers if applicable, and departure. For patients with compromised mobility or requiring medical support during transfer, medical-grade transport with trained medical escort can be arranged. ACCOMMODATION FOR PATIENT'S ATTENDANT: Because the patient is hospitalised for 30–60 days in a sterile isolation unit where visitor access is strictly regulated, GAF Healthcare pre-books serviced apartments or hospital guesthouse accommodation for the accompanying attendant within walking distance or a short commute from the transplant centre. For the subsequent outpatient phase (weeks 6–16), if the patient is medically discharged from inpatient care, GAF arranges suitable long-stay furnished apartments with housekeeping, proximity to the transplant clinic, and reliable transport links. DEDICATED CASE MANAGER & MEDICAL TRANSLATOR: Each BMT patient is assigned a dedicated GAF Healthcare Case Manager — a medically trained professional who liaises between the patient, the transplant team, and the family throughout the entire journey. For patients whose primary language is not English or the local language of the treatment country, GAF provides professional medical interpreters fluent in Arabic, Russian, French, Swahili, Bengali, and other major languages, available for ward rounds, consent discussions, and physician consultations. Interpretation services are available in-person and via secure video link for remote consultations. TELEMEDICINE & POST-DISCHARGE CO-ORDINATION: GAF Healthcare's platform facilitates virtual follow-up consultations between the transplant physician and the patient's home-country haematologist, ensuring seamless handover of care, transmission of chimerism and MRD results, and guided management of chronic GvHD or immunosuppression tapering remotely. A 24/7 medical helpline is available for emergency guidance throughout the post-transplant period.
Common questions about Bone Marrow Transplant
What is the cost of a Bone Marrow Transplant in India compared to the UAE?
How long do I need to stay in India or the UAE before I am fit to fly home after a Bone Marrow Transplant?
What is the success rate of a Bone Marrow Transplant?
Related pages
How GAF Healthcare Assists in Choosing the Best Hospital for Bone Marrow Transplant in Chennai, India
Discover the Top Hospitals for Bone Marrow Transplant in Chennai, India
This page lists 8 accredited medical oncology hospitals in Chennai, India, so you can compare accreditation, specialties and bed capacity in one place.
Support When You Need It Most
Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.
Transparent, All-Inclusive Costs
We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.
Visa, Travel and Stay Coordination
Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.
Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.
Frequently asked questions about bone marrow transplant in Chennai, India
How many medical oncology hospitals are listed in Chennai, India?
How do you choose which hospitals to list?
How much does treatment cost in India?
Are there medical oncology hospitals for this in other India cities?
Next Step
Share your medical reports with us and our team will recommend a hospital and treatment plan for bone marrow transplant in Chennai, India.
Contact us to report an inaccuracy on this page.